Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Feb 7;17(2):219.
doi: 10.3390/ph17020219.

Lipid Disorders Management Strategies (2024) in Prediabetic and Diabetic Patients

Laura Gaita  1   2 , Bogdan Timar  1   2 , Romulus Timar  1   2 , Zlatko Fras  3   4 , Dan Gaita  5   6 , Maciej Banach  7   8   9
Affiliations
Review

Lipid Disorders Management Strategies (2024) in Prediabetic and Diabetic Patients

Laura Gaita et al. Pharmaceuticals (Basel). .

Abstract

Dyslipidaemia is a modifiable risk factor commonly associated with diabetes mellitus and prediabetes, with a major impact on the early development of atherosclerotic cardiovascular disease. Various studies have tried to identify the key treatment targets, their optimal values according to patients' CV risk, and the most efficient yet safe therapeutic agents which, alongside lifestyle changes, would improve lipid levels and reduce cardiovascular mortality and morbidity. Currently, there are multiple pharmacologic options that can be used in the management of dyslipidaemia, such as statins, ezetimibe, bempedoic acid, PCSK9 inhibitors, n-3 polyunsaturated fatty acids or fibrates, to name only a few, while many other are under development. In the current setting of a continuously increasing population of patients with metabolic disorders, this review aims to summarise current knowledge regarding lipid disorders and the recommendations of recent guidelines in treating dyslipidaemia in patients with diabetes mellitus or prediabetes.

Keywords: LDLc; atherogenic dyslipidaemia; cardiovascular risk; diabetes mellitus; lipid-lowering pharmacologic agents; non-HDLc; prediabetes; treatment targets.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Lipid disorders management strategy in patients with DM.
See this image and copyright information in PMC

References

    1. Vaduganathan M., Mensah G.A., Turco J.V., Fuster V., Roth G.A. The Global Burden of Cardiovascular Diseases and Risk: A Compass for Future Health. J. Am. Coll. Cardiol. 2022;80:2361–2371. doi: 10.1016/j.jacc.2022.11.005. - DOI - PubMed
    1. Dal Canto E., Ceriello A., Ryden L., Ferrini M., Hansen T.B., Schnell O., Standl E., Beulens J.W. Diabetes as a cardiovascular risk factor: An overview of global trends of macro and micro vascular complications. Eur. J. Prev. Cardiol. 2019;26((Suppl. S2)):25–32. doi: 10.1177/2047487319878371. - DOI - PubMed
    1. Cai X., Zhang Y., Li M., Wu J.H., Mai L., Li J., Yang Y., Hu Y., Huang Y. Association between prediabetes and risk of all cause mortality and cardiovascular disease: Updated meta-analysis. BMJ. 2020;370:m2297. doi: 10.1136/bmj.m2297. - DOI - PMC - PubMed
    1. Berberich A.J., Hegele R.A. A Modern Approach to Dyslipidemia. Endocr. Rev. 2022;43:611–653. doi: 10.1210/endrev/bnab037. - DOI - PMC - PubMed
    1. Martone A.M., Landi F., Petricca L., Paglionico A., Liperoti R., Cipriani M.C., Ciciarello F., Rocchi S., Calvani R., Picca A., et al. Prevalence of dyslipidemia and hypercholesterolemia awareness: Results from the Lookup 7+ online project. Eur. J. Public Health. 2022;32:402–407. doi: 10.1093/eurpub/ckab224. - DOI - PMC - PubMed

LinkOut - more resources